Matches in Wikidata for { <http://www.wikidata.org/entity/Q37701250> ?p ?o ?g. }
- Q37701250 description "article científic" @default.
- Q37701250 description "article scientifique" @default.
- Q37701250 description "articolo scientifico" @default.
- Q37701250 description "artigo científico" @default.
- Q37701250 description "artículu científicu espublizáu en 2016" @default.
- Q37701250 description "bilimsel makale" @default.
- Q37701250 description "scientific article published on 14 December 2016" @default.
- Q37701250 description "vedecký článok" @default.
- Q37701250 description "vetenskaplig artikel" @default.
- Q37701250 description "videnskabelig artikel" @default.
- Q37701250 description "vědecký článek" @default.
- Q37701250 description "wetenschappelijk artikel" @default.
- Q37701250 description "wissenschaftlicher Artikel" @default.
- Q37701250 description "наукова стаття, опублікована в грудні 2016" @default.
- Q37701250 description "научни чланак" @default.
- Q37701250 description "مقالة علمية نشرت في 14 ديسمبر 2016" @default.
- Q37701250 name "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 name "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 name "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 type Item @default.
- Q37701250 label "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 label "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 label "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 prefLabel "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 prefLabel "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 prefLabel "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 P1433 Q37701250-428E1488-FA21-4127-B555-9932E7D247C8 @default.
- Q37701250 P1476 Q37701250-DCA172C8-344D-493E-AF12-DAF2AFED8276 @default.
- Q37701250 P2093 Q37701250-189A2E95-EF03-4C80-8158-B845D8428CBA @default.
- Q37701250 P2093 Q37701250-2F636C58-9B43-459C-A7DA-1F893D228982 @default.
- Q37701250 P2093 Q37701250-4C336B72-520E-493C-91D2-6A3CD9A60B48 @default.
- Q37701250 P2093 Q37701250-5B134C30-817F-4E3A-B5B5-DA744B751912 @default.
- Q37701250 P2093 Q37701250-640BC547-5084-43E3-8C5B-C91FA7B422A6 @default.
- Q37701250 P2093 Q37701250-65F2828A-60BD-4E6F-B693-29A4080A4100 @default.
- Q37701250 P2093 Q37701250-8D1058E9-007C-44AC-81E7-48FD4CDB5B72 @default.
- Q37701250 P2093 Q37701250-9C591D46-2885-4BFF-B0B4-963005566E3B @default.
- Q37701250 P2093 Q37701250-A5A3A65D-871A-4CA8-BFF6-F4DADB4BCD39 @default.
- Q37701250 P2093 Q37701250-BBE4484B-C815-4A54-A23C-165CFFCA2FF4 @default.
- Q37701250 P2093 Q37701250-C2468DE5-680D-490B-BFE3-7E78A0719351 @default.
- Q37701250 P2093 Q37701250-EAFCDC75-16EB-41D4-AF93-EF85409848B4 @default.
- Q37701250 P2093 Q37701250-F019DFBD-B6AD-4F81-A6ED-620B176E82D5 @default.
- Q37701250 P2093 Q37701250-FC525FA5-EDA4-4E9F-B0A1-624E1C8E3330 @default.
- Q37701250 P2860 Q37701250-2C7D5B01-7BFF-4600-B859-3C1837A58304 @default.
- Q37701250 P2860 Q37701250-4EA03D6B-5234-4D31-8E87-DA46E536F1EE @default.
- Q37701250 P2860 Q37701250-5B5C1744-A014-4301-9034-96A890392E4E @default.
- Q37701250 P2860 Q37701250-5C01876C-FF40-4249-84D0-79C7D14CD517 @default.
- Q37701250 P2860 Q37701250-7B137B8B-21E8-4D1B-813F-4FDA25E4D4A2 @default.
- Q37701250 P2860 Q37701250-7B8937E2-5D53-4E8B-9665-C1A5B92AD748 @default.
- Q37701250 P2860 Q37701250-7F8DB128-DCAA-43AD-91B0-A9BA497180F7 @default.
- Q37701250 P2860 Q37701250-8C5A8FCE-B2D7-4D6C-9CD5-89576AE52F77 @default.
- Q37701250 P2860 Q37701250-8E4D6CF3-3D5C-49E2-B806-EEEC12A8B0F6 @default.
- Q37701250 P2860 Q37701250-9F523E13-317E-4FD6-A20A-6D38E1CFE3CA @default.
- Q37701250 P2860 Q37701250-A2491AB4-EF01-4251-AD90-C125D3FBDD42 @default.
- Q37701250 P2860 Q37701250-A3835065-461B-423A-AF63-85CA1B46D7CA @default.
- Q37701250 P2860 Q37701250-A54E0B6D-A1FE-4B14-9398-0399F5F5F138 @default.
- Q37701250 P2860 Q37701250-ABD7B3DB-2B64-4E59-A7F8-E5D387265711 @default.
- Q37701250 P2860 Q37701250-BABAFDCF-F693-4139-8B7C-21ACEA57661B @default.
- Q37701250 P2860 Q37701250-C02057E1-CA23-4A1E-8BBE-164776C4D291 @default.
- Q37701250 P2860 Q37701250-D783AF9E-5428-4C96-93AB-ECB9493465AF @default.
- Q37701250 P2860 Q37701250-E51C5B9E-2ECA-4BC9-A6F1-D02E2A516529 @default.
- Q37701250 P2860 Q37701250-FC21E764-6194-4374-B58F-CCE3308F94B1 @default.
- Q37701250 P304 Q37701250-210DEA0C-2030-4C49-88B7-E84B104769CF @default.
- Q37701250 P31 Q37701250-24CC869C-F164-482D-84CC-19E300CD18A3 @default.
- Q37701250 P356 Q37701250-05810B95-E139-4D3A-A270-143AA2674A73 @default.
- Q37701250 P433 Q37701250-26F6CE38-5900-4308-8EBB-D8146D3994FC @default.
- Q37701250 P478 Q37701250-1F950D9C-8F5F-460D-AA91-648501D4DDC4 @default.
- Q37701250 P50 Q37701250-980C6817-3719-44C8-AA72-1A2486DD6E68 @default.
- Q37701250 P577 Q37701250-EA53DD71-A22C-4480-AC8C-00D00D760142 @default.
- Q37701250 P698 Q37701250-A9B05F71-AE7D-4A0D-8E12-5F12B384DB99 @default.
- Q37701250 P921 Q37701250-054DA5C3-AB2E-420C-9653-73AB290F8A22 @default.
- Q37701250 P921 Q37701250-3C30F905-2AA5-4E4F-B4EB-95873178FDC9 @default.
- Q37701250 P921 Q37701250-5674F7EE-8AF3-4ED3-913A-9D2598DA22A0 @default.
- Q37701250 P921 Q37701250-6423716E-E09F-45F4-AFE0-6A9BB88740D8 @default.
- Q37701250 P921 Q37701250-848BF2FF-B4A3-4AC9-AF3D-D133B865BF95 @default.
- Q37701250 P921 Q37701250-A139DE27-E241-429E-AF9A-35AE0F3A1296 @default.
- Q37701250 P921 Q37701250-E52DC644-C93B-4BB3-95FE-AF62BAC0124E @default.
- Q37701250 P932 Q37701250-8281E121-99CF-4712-BCCB-AE25066F6289 @default.
- Q37701250 P356 OL.2016.5505 @default.
- Q37701250 P698 28356954 @default.
- Q37701250 P1433 Q20640514 @default.
- Q37701250 P1476 "Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)." @default.
- Q37701250 P2093 "Akira Takehara" @default.
- Q37701250 P2093 "Chihiro Tanaka" @default.
- Q37701250 P2093 "Genichi Nishimura" @default.
- Q37701250 P2093 "Hidehito Fujita" @default.
- Q37701250 P2093 "Junichi Sakamoto" @default.
- Q37701250 P2093 "Keishi Nakamura" @default.
- Q37701250 P2093 "Ken Kondo" @default.
- Q37701250 P2093 "Kenji Doden" @default.
- Q37701250 P2093 "Kenji Kobayashi" @default.
- Q37701250 P2093 "Masanori Kotake" @default.
- Q37701250 P2093 "Masato Kataoka" @default.
- Q37701250 P2093 "Naoki Nagata" @default.
- Q37701250 P2093 "Toru Aoyama" @default.
- Q37701250 P2093 "Yoshinori Munemoto" @default.
- Q37701250 P2860 Q27861047 @default.
- Q37701250 P2860 Q28036747 @default.
- Q37701250 P2860 Q28131668 @default.
- Q37701250 P2860 Q29616236 @default.
- Q37701250 P2860 Q29619648 @default.